NCT06947980 Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
| NCT ID | NCT06947980 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Keymed Biosciences Co.Ltd |
| Condition | Atopic Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-06-19 |
| Primary Completion | 2026-07-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 200 participants in total. It began in 2025-06-19 with a primary completion date of 2026-07-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of AD for at least 1 year according to the American Academy of Dermatology's consensus criteria prior to the screening visit meeting all of the following criteria: * EASI≥16 at Screening and Baseline visits; * Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits; * 10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits; * Mean of weekly Pruritus Numeric Rating Scale (NRS) severity score≥4 at Baseline; Exclusion Criteria: * Not enough washing-out period for previous therapy. * Concurrent disease/status which may potentially affect the efficacy/safety judgement. * Organ dysfunction. * Pregnancy. * Other.
Contact & Investigator
Jianzhong Zhang
PRINCIPAL INVESTIGATOR
Peking University People's Hospital
Frequently Asked Questions
Who can join the NCT06947980 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06947980 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06947980 currently recruiting?
Yes, NCT06947980 is actively recruiting participants. Contact the research team at qianjia@keymedbio.com for enrollment information.
Where is the NCT06947980 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06947980 clinical trial?
NCT06947980 is sponsored by Keymed Biosciences Co.Ltd. The principal investigator is Jianzhong Zhang at Peking University People's Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.